bedrocan

Bedromed drops

Oromucosal drops

Bedromed drops is a pharmaceutical grade cannabinoid formulation derived from Bedrocan's standardised *Cannabis sativa* L. chemovars. It is formulated for oromucosal administration in a medium chain triglyceride (MCT) solution. MCT serves as a stable, well-tolerated lipophilic carrier suited to cannabinoid solubility, supporting consistent dosing and individualised titration.

Product information

- Derived from full-spectrum extract of the well-established **Bedrocan® chemovar** 'Afina'
- Preserved **natural cannabinoid and terpene profile** through a specialised manufacturing process
- Guaranteed pharmaceutical-grade quality through **EU-GMP certified manufacturing**

MADE in the EU

Active Substance	Formulation	Starting Material*	Carrier Oil	Shelf Life	Packaging Size
THC	**25 mg/mL**	Bedrocan®	MCT	24 months	30 mL
THC CBD	**10 mg/mL** **10 mg/mL**	Bedrocan®	MCT	24 months	30 mL
THC CBD	**25 mg/mL** **25 mg/mL**	Bedrocan®	MCT	24 months	30 mL

THC dominant Balanced

*) **Bedrocan**, *Cannabis sativa* L. 'Afina'



Medicine status

Bedromed drops is available on prescription only, subject to national cannabis and controlled substance regulations.

Intended use: Direct use or pharmacy compounding, based on regulatory classification in the respective market.

About Bedrocan

Bedrocan is recognised as a pioneer in the production of pharmaceutical-grade medicinal cannabis. Since 2003, Bedrocan has supplied cannabis flower products manufactured to pharmaceutical standards, ensuring quality, safety, and reproducibility for inhalation therapies. To address evolving clinical needs, Bedrocan has expanded its portfolio to include EU-GMP-certified oromucosal dosage forms such as Bedromed drops.

Clinical use

Intended use (emerging clinical evidence): Bedromed drops is supplied under special access provisions as an unapproved oromucosal formulation. Current research on the pharmacological class of THC-containing medicine has explored potential effects on pain perception and spasticity across several clinical conditions. Further clinical trials are required to determine the safety and efficacy of Bedromed drops. **Warnings and precautions**: Absolute and relative contraindications apply. Potential for medicine interactions must be considered.

Dosing & titration

More info?
See **Treatment Planning**

Oromucosal drops, administered by syringe delivering 0.1 mL to 1.0 mL of solution.

Individualised dose titration

Principle: Start low, go slow. Maximum: 0.6 mL per day (equivalent to 15.0 mg THC).

Titration schedule (days 1–12)

A titration period is required to reach the optimal single dose and total daily dosage. The number and timing of doses should be tailored to the indication and adjusted according to individual response and tolerability.

- Stepwise escalation every 2 days, balancing morning and evening doses
- Starting dose is 0.1 mL at day 1-2 (equivalent to 2.5 mg THC daily)
- Maximum recommended daily dose is 0.6 mL at day 11–12 (equivalent to 15 mg THC daily)
- A stepwise escalation schedule over 12 days is suggested

Ordering

Ordering process for pharmacies

You can find ordering details at **www.bedrocan.com/order**.
The Certificate of Analysis (latest batch) is available from your distributor or pharmacy.

Contact Bedrocan
info@bedrocan.com
bedrocan.com